More information: Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma, Clinical ...

Rigel, of South San Francisco, California, is positioning R788 (tamatinib fodium), an inhibitor of Syk kinase, as a direct challenger to the tumor necrosis factor-alpha (TNF-α) inhibitor biologics.

and spleen tyrosine kinase (Syk) targets are closer to the cell surface, and seem more promising targets than the MAPK family. 10 The success of kinase inhibitors in oncology suggests a role for ...

The team, which published its study, “Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in ...

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our P/B Growth Investor model based on the published strategy of ...

“Our study results show that increased gene activity in the spleen tyrosine kinase pathway could be the ... says that the SYK pathway has previously been linked to other autoimmune diseases ...

Stryker's Inks Deal to Aid Its Pain Management Portfolio Stryker Corporation (NYSE: SYK) recently announced a definitive agreement to acquire Vertos Medical Inc., a privately held company ...

A month has gone by since the last earnings report for Stryker (SYK). Shares have added about 8.8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

Stryker Corporation SYK has entered into a definitive agreement to acquire care.ai, a privately held company specializing in artificial intelligence (AI)-assisted virtual care workflows ...

Stryker (SYK) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.79 per share. This compares to earnings of $2.54 per share a year ago. These figures ...